Anti‐FIRΔexon2 autoantibody as a novel indicator for better overall survival in gastric cancer

There is no clinically available biomarker for efficiently indicating the overall survival or therapy response of gastric cancer (GC). The autoantibodies (Abs) in the sera of anti‐far‐upstream element‐binding protein‐interacting repressor‐lacking exon2 (FIRΔexon2), anti‐sorting nexin 15, and anti‐sp...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Sci
Hlavní autoři: Kobayashi, Sohei, Hiwasa, Takaki, Ishige, Takayuki, Kano, Masayuki, Hoshino, Tyuji, Rahmutulla, Bahityar, Seimiya, Masanori, Shimada, Hideaki, Nomura, Fumio, Matsubara, Hisahiro, Matsushita, Kazuyuki
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2021
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7894018/
https://ncbi.nlm.nih.gov/pubmed/33306856
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14767
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky